Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BMY (bristol myers squibb) -- Ignore unavailable to you. Want to Upgrade?

To: OldAIMGuy who wrote (71)	3/4/2000 6:39:00 PM
From: Rob Loney	Read Replies (1) \| Respond to of 194

I thought BMY was a screaming value at $60.00. I guess I won't quit my pharmaceutical day job to be a trader. To take $6.00-$10 off the share price due to the impending loss of TAXOL, shows a lack of knowledge about the importance of this business to BMY. An even greater kind of drop happened to WLA when Rezulin was implicated in some cases of liver damage. It turned out to be the biggest buying opportunity in the great run up of WLA due to Lipitor sales. I believe this represents a similar opportunity prior to the great run up of BMY, due to the impending launch of omapatrilat. Any thoughts?